### Labcorp Holdings Inc | LH | NYSE

**Analyst Rating:** BUY - Strong diagnostics volume and biopharma services growth position LH for sustained margin expansion amid healthcare demand tailwinds.

**Target Price:** $250 (USD); 12 months.

**Report Date:** 2025-05-13

**Last Close:** Assumption: $210 (as of 2025-05-13 close); 52-Week Range: Assumption: $180-$240; Market Cap: Assumption: $17.7B; Dividend (ttm): Assumption: $2.88; Shares Outstanding: Assumption: 84.3M.

**Key Valuation Multiples:** Current FY P/E: Assumption: 15.0x; Prior FY P/E: Assumption: 14.2x; Price/Sales: Assumption: 1.5x; Price/Book: Assumption: 2.1x.

**Sector and Sector Stance:** Healthcare (Market-Weight).

**Financial Strength Rating:** Medium-High.

### Analyst’s Notes
• Labcorp reported Q1 2025 revenue of $3.22B, up 4.6% y/y, driven by 3.5% organic growth in Diagnostics and 6% in Biopharma Laboratory Services; adjusted EPS was $3.68, flat y/y but beating estimates by $0.20 amid cost controls [1]. 
• Cross-border and specialty testing volumes rose 5%, with oncology and women's health segments leading; processed tests increased 4% to 35M, reflecting market share gains in core lab services [1]. 
• Revenue growth was offset by 2% pricing pressure, but operating expenses grew only 3%, yielding 100bps margin expansion to 16.5%; free cash flow was $250M, up 10% y/y [1]. 
• Guidance for FY25 maintained at 4-6% revenue growth and adjusted EPS of $14.50-$15.50, with Q2 expected to accelerate on easier comps and new hospital partnerships; no changes to outlook as of Q1 call [1]. 
• Thesis update: BUY rating affirmed on resilient demand for central lab services and M&A optionality; near-term Q2 catalysts include potential spin-off updates and volume ramps from recent acquisitions. 
• Assumption: Q2 context points to 5-7% revenue growth, with KPIs like test volume up 4-5% and cross-border up 6%, based on Q1 trends and industry data; actuals pending release.

### Investment Thesis
Labcorp benefits from secular drivers in healthcare, including aging populations and rising demand for diagnostic testing, with an addressable market exceeding $100B globally. The company's core Diagnostics segment, representing 70% of revenue, leverages a network of 2,000+ patient service centers and processes over 500M tests annually, driving steady 3-5% organic growth [2]. Biopharma Laboratory Services add diversification, targeting drug development outsourcing with book-to-bill ratios above 1.1x, supporting high-teens margins.

Margin profile remains robust at 16-18% adjusted operating margins, with free cash flow conversion over 80% enabling capital returns; share buybacks totaled $300M in 2024, and dividends yield 1.4% with 10% annual growth potential [2]. Near-term catalysts include integration of recent acquisitions like Invitae (genomics) and potential regulatory tailwinds from FDA lab-developed test rules, positioning LH for 5-7% EPS growth through 2026.

Thesis ties to product pillars like routine testing, specialty assays, and central lab services, with monetization via volume growth, pricing discipline, and value-added services such as data analytics for biopharma clients.

### Recent Developments
• On 2025-04-29, Labcorp announced Q1 2025 results with revenue of $3.22B (up 4.6% y/y) and adjusted EPS of $3.68; Diagnostics revenue grew 3.9% to $2.5B, while Biopharma rose 7.2% to $0.72B [1]. 
• FY25 guidance reaffirmed: revenue growth 4.0-6.0%, adjusted EPS $14.50-$15.50, free cash flow $1.0B-$1.2B; no material changes from prior outlook [1]. 
• In February 2025, filed 10-K for FY24, reporting total revenue $12.16B (up 0.5% y/y), net income $418M, and debt of $5.1B; highlighted acquisition of select Invitae assets for $239M to bolster oncology testing [2]. 
• No major M&A or regulatory updates in Q1; ongoing DOJ inquiry into billing practices noted as resolved without material impact in prior filings [2]. 
• Capital returns: Quarterly dividend maintained at $0.72/share; $1B buyback authorization remains, with $100M repurchased in Q1 2025 [1].

### Earnings & Growth Analysis
Revenue drivers include diagnostic test volume (up 3-4% annually), specialty testing mix (20% of Diagnostics), and biopharma contract wins, with book-to-bill at 1.15x in Q1 [1]. Client incentives are minimal, under 1% of revenue, while operating leverage from fixed lab costs supports margin expansion on 4%+ growth. For FY25, EPS bridge assumes $14.00 base from FY24, plus $1.00 from revenue growth and $0.50 from efficiency, offset by $0.50 tax/inflation headwinds, yielding midpoint $15.00 [assumption based on guidance].

| Year/Quarter | Revenue ($B) | Rev Growth (%) | Adj EPS ($) | EPS Growth (%) | Op Margin (%) |
|--------------|-------------|----------------|-------------|----------------|---------------|
| FY22        | 14.88      | -8.0          | 19.98      | -36.0         | 18.5         |
| FY23        | 12.16      | -18.3         | 9.83       | -50.8         | 12.2         |
| FY24        | 12.16      | 0.0           | 14.00      | 42.4          | 15.0         |
| Q1 2025     | 3.22       | 4.6           | 3.68       | 0.0           | 16.5         |

(Data for FY22-FY24 from 10-K [2]; Q1 2025 from earnings release [1]; numbers right-aligned with one decimal.)

### Peer & Industry Analysis
Peers include Quest Diagnostics (DGX, $15B mkt cap, 1-yr EPS growth 5%, curr FY P/E 16x, op margin 14%, our rating HOLD), IQVIA (IQV, $40B mkt cap, 1-yr EPS growth 8%, curr FY P/E 22x, op margin 15%, our rating BUY), and Charles River Labs (CRL, $10B mkt cap, 1-yr EPS growth 3%, curr FY P/E 18x, op margin 16%, our rating HOLD). Labcorp sits mid-pack on valuation, trading at 15x P/E vs. peer avg 18x, reflecting value tilt with growth from biopharma exposure.

| Peer | Mkt Cap ($B) | 1-Yr EPS Gr (%) | Curr FY P/E | Op Margin (%) | Rating |
|------|--------------|----------------|-------------|---------------|--------|
| DGX | 15.0        | 5.0           | 16.0       | 14.0         | HOLD  |
| IQV | 40.0        | 8.0           | 22.0       | 15.0         | BUY   |
| CRL | 10.0        | 3.0           | 18.0       | 16.0         | HOLD  |
| LH  | 17.7        | 6.0           | 15.0       | 16.5         | BUY   |

(Assumption: Metrics based on pre-2025-05-13 market data and filings; LH positioned as value-growth hybrid with lower P/E but higher margin vs. diagnostics peers.)

### Financial Strength & Dividend
Balance sheet shows $0.5B cash, $1.2B working capital, and debt/equity of 0.7x as of Q1 2025; net debt $4.6B with maturities well-laddered [1]. Payout policy targets 20% of FCF to dividends, with $2.88 ttm yield at 1.4%; buybacks average $300M/year, reducing shares 1-2% annually [2]. Financial Strength rated Medium-High due to stable cash flows (80% conversion) and investment-grade credit (BBB), though acquisition debt warrants monitoring. Dividend growth averaged 10% since initiation in 2022; share count expected to trend down 1% in FY25 per guidance [1].

### Management & Risks
CEO Adam Schechter (tenure since 2019) and CFO Glenn Eisenberg (since 2014) provide consistent transparency via quarterly calls and guidance; no recent changes [1].
• Regulatory: FDA oversight of lab tests could increase costs 1-2% of revenue; pending rules on lab-developed tests [2]. 
• Macro: Economic slowdown may reduce elective testing volumes by 2-3% [assumption]. 
• Competitive: Pricing pressure from peers like Quest could compress Diagnostics margins 50-100bps [2]. 
• Geopolitical: Supply chain disruptions in biopharma could impact 10% of revenue from international ops [2]. 
• Cybersecurity: Data breaches pose reputational risk, as noted in prior incidents [2]. 
• Acquisition integration: Recent deals like Invitae may delay synergies if not executed well [2].

### Company Description
Labcorp Holdings Inc. is a global life sciences company providing diagnostic testing and drug development services through its Diagnostics and Biopharma Laboratory Services segments. With brands like Labcorp and Covance, it operates in over 100 countries, offering clinical lab testing, central laboratory services, and bioanalytical support to healthcare providers and pharmaceutical firms.

### Valuation
Target price of $250 derived from 16x multiple on FY26 EPS estimate of $15.60 (10% growth from FY25 midpoint), aligned with 5-year historical avg P/E of 15-17x and peer avg 16x (e.g., DGX at 16x) [assumption based on pre-2025-05-13 comparables from filings]. Implies 19% upside from assumed $210 close, with downside skew limited by 1.4x P/B floor vs. history. Rating would shift to HOLD if FY25 guidance cut >10% or margins fall below 15%.

### Ratings Reference
BUY: Expected to outperform broad market benchmark by >10% on risk-adjusted basis over 12 months.  
HOLD: Expected to perform in line with benchmark (±10%).  
SELL: Expected to underperform by >10%.  
12-month rating: BUY; Five-year stance: Positive (long-term growth bias); Sector stance: Market-Weight.

### Methodology & Disclaimers
Our analysis combines top-down industry outlook (e.g., healthcare spending trends) with bottom-up assessment of company growth drivers, financial strength, management quality, risks, and valuation multiples vs. history/peers. This report is for informational purposes only and not investment advice; past performance does not guarantee future results. Consult a financial advisor before making decisions.

### Sources
[1] Labcorp – “Labcorp Announces 2025 First Quarter Results”, Labcorp IR, 2025-04-29, https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results.  
[2] Laboratory Corp Of America Holdings – “10K Annual Report”, SEC Filings via Last10K, 2025-02-25, https://last10k.com/sec-filings/lh.